NEUROCRINE BIOSCIENCES INC
For the period ended Mar 31, 2024. Filed May 1, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the period from January 1, 2024, to March 31, 2024, our executive officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
| Name and Title | Action | Date | Trading Arrangement | Total Shares Authorized to be Sold | Expiration Date |
|---|---|---|---|---|---|
| Rule 10b5-1* · Non-Rule 10b5-1** | |||||
| Julie S. Cooke | Adopt | 3/17/2024 | X | 88,495 | 6/13/2025 |
| Chief Human Resources Officer | |||||
| Kyle W. Gano | Adopt | 3/15/2024 | X | 101,400 | 5/10/2025 |
| Chief Business Development & Strategy Officer | |||||
| Matthew C. Abernethy | Adopt | 2/13/2024 | X | 45,000 | 2/15/2025 |
| Chief Financial Officer | |||||
| Gary A. Lyons | Adopt | 2/13/2024 | X | 25,000 | 5/27/2025 |
| Director | |||||
*Intended to satisfy the affirmative defense of Rule 10b5-1(c)
**Not intended to satisfy the affirmative defense of Rule 10b5-1(c)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.